Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study.
Nat Commun
; 6: 7633, 2015 Jul 07.
Article
em En
| MEDLINE
| ID: mdl-26151496
ABSTRACT
Graves' disease is the leading cause of hyperthyroidism affecting 1.0-1.6% of the population. Antithyroid drugs are the treatment cornerstone, but may cause life-threatening agranulocytosis. Here we conduct a two-stage association study on two separate subject sets (in total 42 agranulocytosis cases and 1,208 Graves' disease controls), using direct human leukocyte antigen genotyping and SNP-based genome-wide association study. We demonstrate HLA-B*3802 (Armitage trend Pcombined=6.75 × 10(-32)) and HLA-DRB1*0803 (Pcombined=1.83 × 10(-9)) as independent susceptibility loci. The genome-wide association study identifies the same signals. Estimated odds ratios for these two loci comparing effective allele carriers to non-carriers are 21.48 (95% confidence interval=11.13-41.48) and 6.13 (95% confidence interval=3.28-11.46), respectively. Carrying both HLA-B*3802 and HLA-DRB1*0803 increases odds ratio to 48.41 (Pcombined=3.32 × 10(-21), 95% confidence interval=21.66-108.22). Our results could be useful for antithyroid-induced agranulocytosis and potentially for agranulocytosis caused by other chemicals.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Antitireóideos
/
Predisposição Genética para Doença
/
Agranulocitose
/
Estudo de Associação Genômica Ampla
/
Genótipo
/
Antígenos HLA
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article